41 peer-reviewed studies · Evidence score: 8.5/10
Wang C et al. • Journal of ethnopharmacology (2024)
Compared with conventional treatment, adjuvant treatment with CS of lung cancer not only improve TRR, QOL and immune function, but also reduce the incidence of ADRs and radiation pneumonitis.
Zhang HW et al. • The Cochrane database of systematic reviews (2014)
We found that Cordyceps preparation, as an adjuvant therapy to conventional medicine, showed potential promise to decrease serum creatinine, increase creatine clearance, reduce proteinuria and alleviate CKD-associated complications, such as increased haemoglobin and serum albumin.
Luo Y et al. • Renal failure (2015)
However, with regard to low-quality and significant heterogeneity of included trials, to further verify the current results from this meta-analysis, long-term and well-designed RCTs with high-quality study are warranted to ascertain the long-term efficacy of O. sinensis.
de Sousa TK et al. • Pathogens (Basel, Switzerland) (2025)
In future research, the development of integrated guidelines that simultaneously consider human, animal, and environmental health is recommended.
Chen X et al. • PloS one (2014)
These issues should be addressed in future trials.
Bee Yean O et al. • Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan (2019)
Given the small number of trials included, the unclear methodological quality of the included trials, and the high heterogeneity in pooled analyses, the evidence obtained in this review is insufficient to recommend the use of cordyceps as adjunctive treatment in hemodialysis patients.
Gong P et al. • Molecular nutrition & food research (2025)
Future research should address these gaps, emphasizing personalized interventions and advanced technologies for next-generation antidepressant foods.
Hong T et al. • The Cochrane database of systematic reviews (2015)
Although there were some favourable aspects associated with Cordyceps, longer-term studies are needed to clarify any benefit-harm trade-off.
Yao L et al. • International journal of biological macromolecules (2024)
Nevertheless, there remain unknown elements that continue to influence SAR, leaving room for further exploration.
Ma G et al. • Pharmaceutical biology (2024)
Bailing capsules have shown promising results in the treatment of stable COPD.
Lin Y et al. • Gastroenterology (2022)
This study reveals enteric mycobiota signatures and pathogenic fungi in stages of colorectal tumorigenesis.
Narayanan S et al. • Current oncology reports (2023)
More trials are needed to explore mushroom use during and after cancer treatment.
Sun YJ et al. • Bratislavske lekarske listy (2017)
Medication can reduce the IL-10 level, regulate the equilibrium of pro-inflammatory and anti-inflammatory factors, and decrease the level of caspase 1 and IL-18 (Tab. 2, Fig. 1, Ref. 18).
Yang EJ et al. • Phytotherapy research : PTR (2026)
In vitro, in vivo, and clinical trial results indicate that CM is safe for administration and shows promise for developing functional foods having various efficacies such as immunomodulation, anti-tumor, and neuroprotection.© 2025 John Wiley & Sons Ltd.
Li S et al. • Journal of evidence-based medicine (2025)
YChCC represent a promising adjuvant therapy for patients with stable COPD, ranging from mild to severe.
Chang HH et al. • International journal of medicinal mushrooms (2022)
Therefore, C. cicadae mycelium supplementation may be used for dry eye alleviation as a novel therapeutic intervention.
Shen S et al. • Journal of cosmetic dermatology (2025)
Our study demonstrated that both oral TXA combined with hydroquinone cream and oral TXA combined with Cordyceps essence significantly improved melasma in women.
Ontawong A et al. • Scientific reports (2024)
This rct examined the effects of Beta-Sitosterol.
Kai Z et al. • Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan (2015)
DCXC treatment may protect against CIN in patients with type 2 diabetes and renal insufficiency undergoing coronary angiography, with intensive DCXC therapy being more effective.
Xu G et al. • Journal of clinical pharmacy and therapeutics (2014)
These findings suggest that PE patients not responding to an 8-week treatment with sertraline 50 mg can benefit from an additional 4-week treatment with sertraline 100 mg and that the PEDT may be a valid measure of treatment response in PE patients.